Emergence of high-level mupirocin resistance in methicillin-resistant Staphylococcus aureus isolated from Brazilian University Hospitals

Infection Control and Hospital Epidemiology

Volumn 17, Issue 12, 1996, Pages 813-816

  Dos Santos, Kátia Regina Netto ^a   De Fonseca, Leila Souza ^b   Gontijo Filho, Paulo Pinto ^b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; PSEUDOMONIC ACID;

ANTIBIOTIC RESISTANCE; ARTICLE; BRAZIL; CROSS INFECTION; HUMAN; INFECTION CONTROL; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; PENICILLIN RESISTANCE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; UNIVERSITY HOSPITAL;

ANTI-BACTERIAL AGENTS; BRAZIL; CROSS INFECTION; DRUG RESISTANCE, MICROBIAL; HOSPITALS, UNIVERSITY; HUMANS; INFECTION CONTROL; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; MUPIROCIN; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 0030332697     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.2307/30141177     Document Type: Article

References (15)

1. Wey SB. Infection control in a country with annual inflation of 3,600%. Infect Control Hosp Epidemiol 1995;16:175-178.
2. Pannuti CS, Grimbaum RS. An overview of nosocomial infection control in Brazil. Infect Control Hosp Epidemiol 1995;16:170-174.
3. Pereira MCG, Hanna G, Richtmann K, Kusakano EJV, Shamatai Y, Mendonça JS. Perfil atual de sensibilidade de bactérias aos antimicrobianos usuais: análise de 1841 amostras de secreções, sangue, urina e liquor. Presented at the 24th Congresso da Sociedade Brasileira de Medicina Tropical; February 28-March 3, 1988; Manaus, Brazil. Abstract 102.
4. Lofti CJ, Silva JF, Machado AMO, et al. Comparação da susceptibilidade aos antimicrobianos das bactérias isoladas de infecções hospitalares entre os anos de 1986-1987 no Hospital São Paulo. Presented at the 24th Congresso da Sociedade Brasileira de Medicina Tropical; February 28-March 3, 1988; Manaus, Brazil. Abstract 105.
5. Hudson IRB. The efficacy of intranasal mupirocin in the prevention of staphylococcal infections: a review of recent experience. J Hosp Infect 1994;27:81-98.
6. Udo EE, Pearman JR, Grubb WB. Emergence of high-level mupirocin resistance in methicillin-resistant Staphylococcus aureus in western Australia. J Hosp Infect 1994;26:157-165.
7. Layton MC, Perez M, Heald P, Patterson JE. An outbreak of mupirocin-resistant Staphylococcus aureus on a dermatology ward associated with an environmental reservoir. Infect Control Hosp Epidemiol 1993;14:369-375.
8. Smith MD, Sanghrajka M, Lock S. Mupirocin-resistant Staphylococcus aureus. Lancet 1987;2:1472-1473.
9. Cookson BD, Lacey RW, Noble WC, Reeves DS, Wise R, Redhead RJ. Mupirocin-resistant Staphylococcus aureus. Lancet 1990;335:1095-1096.
10. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. 3rd ed. Villanova, PA: NCCLS; 1993. Approved standard:M7-A3.
11. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility Tests. 5th ed. Villanova, PA: NCCLS; 1993. Approved standard:M2-A5.
12. Fuchs PC, Jones RN, Barry AL. Interpretative criteria for disk diffusion susceptibility testing of mupirocin, a topical antibiotic. J Clin Microbiol 1990;28:608-609.
13. Bradley SF, Ramsey MA, Morton TM, Kauffman CA. Mupirocin resistance: clinical and molecular epidemiology. Infect Control Hosp Epidemiol 1995;16:354-358.
14. Casewell MW, Hill RLR. In vitro activity of mupirocin ('pseudomonic acid') against clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 1985;15:523-531.
15. Farr BM. Rifamycins. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 4th ed. New York, NY: Churchill Livingstone; 1995:317-329.